Neurofilament Phosphorylation is Increased in Ventral Horn Neurons of Neonatal Rat Spinal Cord Exposed to Cerebrospinal Fluid from patients with Amyotrophic Lateral Sclerosis (original) (raw)
Related papers
Brain research, 2009
We investigated the effect of Cerebrospinal Fluid (CSF) from sporadic Amyotrophic Lateral Sclerosis patients (SALS-CSF) on motor neuron-like cells to delineate the pathomechanism of SALS. Exposure of NSC-34 cells to SALS-CSF caused lower viability, reduction in differentiation and enhanced lactate dehydrogenase activity. Additionally, reduced choline acetyl transferase expression alongside intracellular aggregation of phosphorylated neurofilaments was prominently seen. The aggregates were immunopositive for ubiquitin. These findings are comparable to the pathological changes seen in the postmortem tissue of ALS patients.
Brain Research, 2009
Cerebro Spinal Fluid (CSF) from patients with ALS has been documented to have a toxic effect on motor neurons both in vivo and in vitro. Here we show that the CSF from Amyotrophic Lateral Sclerosis (ALS) patients (ALS-CSF) has the potential to perturb ion channel expression, specifically the Na v 1.6, and K v 1.6 channels in newborn rat spinal motor neurons both in vivo and in vitro. ALS-CSF and CSF from nonALS patients (nonALS-CSF) were intrathecally injected into 3-day-old rat pups at the rate of 1 μl/2.5 min using a microinjector. In addition, embryonic rat spinal cord cultures were also exposed to 10% ALS or nonALS-CSF on the 9th day in vitro (9DIV) in serum free DMEM medium. After 48 h of CSF exposure, the cultures and the spinal cord sections were processed for immunostaining of the above mentioned ion channels. We observed a decrease in the expression of Na v 1.6 and K v 1.6 channels in motor neurons in ALS-CSF treated group, and the presence of trophic factors like Brain Derived Neurotrophic Factor (BDNF) and Ciliary Neurotrophic Factor CNTF partially reversed the effects produced by ALS-CSF. Altered expression of these voltagegated channels may interfere with the electrical activity of motor neurons, and thereby lead to the degeneration of neurons.
Journal of the Neurological Sciences, 1989
Seven lumbosacral spinal cords with motor neuron disease were examined immunocytochemically with monoclonal antibodies (MAb) directed against neurofilament proteins (NFP). Each of the 5 MAbs used in this study was monospecific to one of the triplet of NFP. Two of them were specific to the highly phosphorylated form of high molecular weight peptide of NFP (NFP-H). All 5 MAbs stained all axonal swellings examined. In 2 spinal cords examined, some axonal swellings were found in the anterolateral funiculus and some of these were as far as 1000 #m from the grey matter. This localization of axonal swellings suggests that a high degree of phosphorylation of NFP is not the cause of accumulation of NFP in axonal swellings in motor neuron disease.
Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis
Journal of Neurology, Neurosurgery & Psychiatry, 1998
The neurofilament protein is a major structural protein of neurons and a marker for axonal damage. The concentrations of the light subunit of the neurofilament triplet protein (NFL) in CSF were significantly increased in patients with relapsing-remitting multiple sclerosis compared with healthy controls (p<0.001). Seventy eight per cent of patients with multiple sclerosis showed increased NFL concentrations. Significant correlations between the NFL concentration in CSF and clinical indices were discerned for disability, exacerbation rate, and time from the start of the previous exacerbation to the time of the lumbar puncture. The results suggest that axonal damage occurs during relapsing-remitting multiple sclerosis and that the damage contributes to disability and the appearance of clinical exacerbations. The concentration of NFL in CSF is a potential marker of disease activity in multiple sclerosis and might be useful in future clinical trials of multiple sclerosis.
Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis
Neurology, 2018
To examine neurofilament (Nf) concentrations according to symptom onset and clinical diagnostic certainty categories of amyotrophic lateral sclerosis (ALS). We measured Nf light chain (NfL) and phosphorylated Nf heavy chain (pNfH) CSF and NfL serum levels in patients with ALS with first symptom onset ≤6 months (n = 54) or >6 months (n = 135) from sampling, and patients with other neurologic diseases, differential diagnoses of a motor neuron disease (MND mimics), and other MND variants to determine the diagnostic accuracy in patients with ALS with early symptom onset. Samples were received multicentric and analyzed by ELISA and Simoa platform and related to other clinical measures. NfL and pNfH in CSF and NfL in serum were increased in early and later symptomatic phase ALS (< 0.0001). CSF and serum NfL and CSF pNfH discriminated patients with ALS with early symptom onset from those with other neurologic diseases and MND mimics with high sensitivity (94%, 88%, 98%, and 89%, 100%...